Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $101.79 --0%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VAXX, EGRX, AFIB, More
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VAXX, EGRX, AFIB, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.63 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- Bernstein SocGen Group Reiterates Outperform Rating on IREN Ltd. (IREN)
- X-Energy, Inc. (XE) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
